Skip to main content

Table 2 Experimental subunit vaccines against Mycoplasma hyopneumoniae tested in mice.

From: Perspectives for improvement of Mycoplasma hyopneumoniae vaccines in pigs

Antigen

Vaccine type

Adjuvant

Route

Nb of vaccinations

Humoral response

CMI responsea

Other/comments

References

Serum

BALFb

P71

Subunit

Mycobacterium tuberculosis ESAT-6 recombinant protein

IM

2

IgG1, IgG2a

IgG2a/IgG1 ≈1 (with) < 1 (without adjuvant)

 

IFN-γ, low Il-10

 

[82]

P97 (R1)

Subunit and its chimeric from with LTBb

 

IM or IN

3

IgG, IgG1, IgG2a (only with chimeric form)

IM: IgG2a/IgG1 = 1.2

IN: IgG2a/IgG1 = 0.6

IgA (only with chimeric form)

IFN-γ response (only with chimeric form and IN application)

No anti-R1 antibodies with commercial bacterin

[83]

P97 (R1,R1R2)

Subunit and their chimeric forms with LTB

Montanide IMS 1113

IM

3

IgG

IgA, IgG

IFN-γ

Highest humoral response with chimeric forms

[84]

HSP70

Subunit

Nanoparticles SBa-15 and SBa-16, Aluminium

IP

3

IgG

 

Only in SBa-15 group; IFN-γ, Il-4, Il-10

Effect SBa-15 comparable to Aluminium

[85]

P97R1, P46, P95, P42

Chimeric – recombinant E. coli bacterin

Oil adjuvant (AddaVaxâ„¢) (for chimeric)

IM

2

IgG, IgG1, IgG2a (IgG2a /IgG1≈0.8)

  

Antibodies against each antigen; higher response in chimeric group

[86]

  1. IM, Intramuscular; IN, Intranasal; IP, Intraperitoneal.
  2. aCMI responses were tested by stimulation of splenocytes.
  3. bBALF bronchoalveolar lavage fluid.
  4. cLTB B subunit of heat-labile enterotoxin of E. coli.